View Item 

Show simple item record

Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology
dc.contributor.authorSinger, Michael C.
dc.contributor.authorMarchal, Francis
dc.contributor.authorAngelos, Peter
dc.contributor.authorBernet, Vic
dc.contributor.authorBoucai, Laura
dc.contributor.authorBuchholzer, Samanta
dc.contributor.authorBurkey, Brian
dc.contributor.authorEisele, David
dc.contributor.authorErkul, Evren
dc.contributor.authorFaure, Frederic
dc.contributor.authorFreitag, Suzanne K.
dc.contributor.authorGillespie, Marion Boyd
dc.contributor.authorHarrell, Richard Mack
dc.contributor.authorHartl, Dana
dc.contributor.authorHaymart, Megan
dc.contributor.authorLeffert, Jonathan
dc.contributor.authorMandel, Susan
dc.contributor.authorMiller, Barbra S.
dc.contributor.authorMorris, John
dc.contributor.authorPearce, Elizabeth N.
dc.contributor.authorRahmati, Rahmatullah
dc.contributor.authorRyan, William R.
dc.contributor.authorSchaitkin, Barry
dc.contributor.authorSchlumberger, Martin
dc.contributor.authorStack, Brendan C.
dc.contributor.authorVan Nostrand, Doug
dc.contributor.authorWong, Ka Kit
dc.contributor.authorRandolph, Gregory
dc.date.accessioned2020-11-04T16:02:53Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-11-04T16:02:53Z
dc.date.issued2020-11
dc.identifier.citationSinger, Michael C.; Marchal, Francis; Angelos, Peter; Bernet, Vic; Boucai, Laura; Buchholzer, Samanta; Burkey, Brian; Eisele, David; Erkul, Evren; Faure, Frederic; Freitag, Suzanne K.; Gillespie, Marion Boyd; Harrell, Richard Mack; Hartl, Dana; Haymart, Megan; Leffert, Jonathan; Mandel, Susan; Miller, Barbra S.; Morris, John; Pearce, Elizabeth N.; Rahmati, Rahmatullah; Ryan, William R.; Schaitkin, Barry; Schlumberger, Martin; Stack, Brendan C.; Van Nostrand, Doug; Wong, Ka Kit; Randolph, Gregory (2020). "Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology." Head & Neck 42(11): 3446-3459.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/163491
dc.description.abstractBackgroundPostoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.MethodsA multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.ResultsConsensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.ConclusionSalivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othersalivary
dc.subject.otherradioactive iodine
dc.subject.otherlacrimal
dc.subject.otherrecommendations
dc.subject.otherthyroid cancer
dc.titleSalivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163491/2/hed26417.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163491/1/hed26417_am.pdfen_US
dc.identifier.doi10.1002/hed.26417
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceFallahi B, Beiki D, Abedi SM, et al. Does vitamin E protect salivary glands from I‐131 radiation damage in patients with thyroid cancer? Nucl Med Commun. 2013; 34: 777 ‐ 786.
dc.identifier.citedreferenceSchlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low‐risk thyroid cancer. N Engl J Med. 2012; 366: 1663 ‐ 1673.
dc.identifier.citedreferenceIakovou I, Goulis DG, Tsinaslanidou Z, Giannoula E, Katsikaki G, Konstantinidis I. Effect of recombinant human thyroid‐stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. Head Neck. 2016; 38 ( Suppl 1 ): E227 ‐ E230.
dc.identifier.citedreferenceRosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid‐stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med. 2008; 49: 1776 ‐ 1782.
dc.identifier.citedreferenceMa C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high‐dose radioactive iodine‐treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010; 37: 1778 ‐ 1785.
dc.identifier.citedreferenceBohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high‐dose radioiodine treatment: results of a double‐blind placebo‐controlled study. J Clin Oncol. 1998; 16: 3542 ‐ 3549.
dc.identifier.citedreferenceKim SJ, Choi HY, Kim IJ, et al. Limited cytoprotective effects of amifostine in high‐dose radioactive iodine 131‐treated well‐differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid. 2008; 18: 325 ‐ 331.
dc.identifier.citedreferenceChristou A, Papastavrou E, Merkouris A, Frangos S, Tamana P, Charalambous A. Clinical studies of nonpharmacological methods to minimize salivary gland damage after radioiodine therapy of differentiated thyroid carcinoma: systematic review. Evid Based Complement Alternat Med. 2016; 2016: 6795076.
dc.identifier.citedreferenceNakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005; 46: 261 ‐ 266.
dc.identifier.citedreferenceSilberstein EB. Reducing the incidence of 131I‐induced sialadenitis: the role of pilocarpine. J Nucl Med. 2008; 49: 546 ‐ 549.
dc.identifier.citedreferenceVan Nostrand D, Bandaru V, Chennupati S, et al. Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. Thyroid. 2010; 20: 1113 ‐ 1119.
dc.identifier.citedreferenceNakada K, Satou Y, Tamura M, Tsuruhara R, Sakuma I, Sakurai1 M. Does lemon candy really reduce total amount of radioactivity passing through salivary glands and ducts? [abstract]. J Nucl Med. 2013; 54: 1918.
dc.identifier.citedreferenceKulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun. 2014; 35: 210 ‐ 216.
dc.identifier.citedreferenceUpadhyaya A, Zhou P, Meng Z, et al. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized‐controlled trial. Nucl Med Commun. 2017; 38: 891 ‐ 903.
dc.identifier.citedreferenceSon H, Lee SM, Yoon RG, et al. Effect of selenium supplementation for protection of salivary glands from iodine‐131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med. 2017; 20: 62 ‐ 70.
dc.identifier.citedreferenceLiu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single‐blind, controlled trial. J Nucl Med. 2010; 51: 618 ‐ 623.
dc.identifier.citedreferenceKim HW, Ahn BC, Lee SW, Lee J. Effect of parotid gland massage on parotid gland Tc‐99m pertechnetate uptake. Thyroid. 2012; 22: 611 ‐ 616.
dc.identifier.citedreferenceFox PC, van der Ven PF, Sonies BC, Weiffenbach JM, Baum BJ. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc. 1985; 110: 519 ‐ 525.
dc.identifier.citedreferenceThomson WM, Chalmers JM, Spencer AJ, Williams SM. The Xerostomia inventory: a multi‐item approach to measuring dry mouth. Community Dent Health. 1999; 16: 12 ‐ 17.
dc.identifier.citedreferenceCho MA, Ko JY, Kim YK, Kho HS. Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. J Oral Rehabil. 2010; 37: 185 ‐ 193.
dc.identifier.citedreferencePai S, Ghezzi EM, Ship JA. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91: 311 ‐ 316.
dc.identifier.citedreferenceAubin‐Pouliot A, Delagnes EA, Eisele DW, Chang JL, Ryan WR. The chronic obstructive Sialadenitis symptoms questionnaire to assess sialendoscopy‐assisted surgery. Laryngoscope. 2016; 126: 93 ‐ 99.
dc.identifier.citedreferenceKim YM, Choi JS, Hong SB, Hyun IY, Lim JY. Salivary gland function after sialendoscopy for treatment of chronic radioiodine‐induced sialadenitis. Head Neck. 2016; 38: 51 ‐ 58.
dc.identifier.citedreferenceMoreddu E, Baumstarck‐Barrau K, Gabriel S, et al. Incidence of salivary side effects after radioiodine treatment using a new specifically‐designed questionnaire. Br J Oral Maxillofac Surg. 2017; 55: 609 ‐ 612.
dc.identifier.citedreferenceMalpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys. 1996; 35: 535 ‐ 540.
dc.identifier.citedreferencePniak T, Strympl P, Stanikova L, Zelenik K, Matousek P, Kominek P. Sialoendoscopy, sialography, and ultrasound: a comparison of diagnostic methods. Open Med (Wars). 2016; 11: 461 ‐ 464.
dc.identifier.citedreferenceSobrino‐Guijarro B, Cascarini L, Lingam RK. Advances in imaging of obstructed salivary glands can improve diagnostic outcomes. Oral Maxillofac Surg. 2013; 17: 11 ‐ 19.
dc.identifier.citedreferenceLarson AR, Aubin‐Pouliot A, Delagnes E, Zheng M, Chang JL, Ryan WR. Surgeon‐performed ultrasound for chronic obstructive sialadenitis helps predict sialendoscopic findings and outcomes. Otolaryngol Head Neck Surg. 2017; 157: 973 ‐ 980.
dc.identifier.citedreferenceHorvath E, Skoknic V, Majlis S, et al. Radioiodine‐induced salivary gland damage detected by ultrasonography in patients treated for papillary thyroid cancer: RAI activity and risk. Thyroid. 2020. https://doi.org/10.1089/thy.2019.0563.
dc.identifier.citedreferenceSoo Roh S, Wook Kim D, Jin BH. Association of xerostomia and ultrasonographic features of the major salivary glands after radioactive iodine ablation for papillary thyroid carcinoma. AJR Am J Roentgenol. 2016; 207: 1077 ‐ 1081.
dc.identifier.citedreferenceBrozzi F, Rago T, Bencivelli W, et al. Salivary glands ultrasound examination after radioiodine‐131 treatment for differentiated thyroid cancer. J Endocrinol Invest. 2013; 36: 153 ‐ 156.
dc.identifier.citedreferenceBecker M, Marchal F, Becker CD, et al. Sialolithiasis and salivary ductal stenosis: diagnostic accuracy of MR sialography with a three‐dimensional extended‐phase conjugate‐symmetry rapid spin‐echo sequence. Radiology. 2000; 217: 347 ‐ 358.
dc.identifier.citedreferenceKalinowski M, Heverhagen JT, Rehberg E, Klose KJ, Wagner HJ. Comparative study of MR sialography and digital subtraction sialography for benign salivary gland disorders. AJNR Am J Neuroradiol. 2002; 23: 1485 ‐ 1492.
dc.identifier.citedreferenceGuggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc. 2003; 134: 61 ‐ 69. quiz 118‐119.
dc.identifier.citedreferenceVilla A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2015; 11: 45 ‐ 51.
dc.identifier.citedreferenceWalter MA, Turtschi CP, Schindler C, Minnig P, Muller‐Brand J, Muller B. The dental safety profile of high‐dose radioiodine therapy for thyroid cancer: long‐term results of a longitudinal cohort study. J Nucl Med. 2007; 48: 1620 ‐ 1625.
dc.identifier.citedreferenceVila PM, Olsen MA, Piccirillo JF, Ogden MA. Rates of sialoendoscopy and sialoadenectomy in 5,111 adults with private insurance. Laryngoscope. 2019; 129: 602 ‐ 606.
dc.identifier.citedreferenceDelagnes EA, Aubin‐Pouliot A, Zheng M, Chang JL, Ryan WR. Sialadenitis without sialolithiasis: prospective outcomes after sialendoscopy‐assisted salivary duct surgery. Laryngoscope. 2017; 127: 1073 ‐ 1079.
dc.identifier.citedreferenceFaure F, Boem A, Taffin C, Badot F, Disant F, Marchal F. Diagnostic and interventional sialendoscopy. Rev Stomatol Chir Maxillofac. 2005; 106: 250 ‐ 252.
dc.identifier.citedreferenceCanzi P, Cacciola S, Capaccio P, et al. Interventional sialendoscopy for radioiodine‐induced sialadenitis: quo vadis? Acta Otorhinolaryngol Ital. 2017; 37: 155 ‐ 159.
dc.identifier.citedreferenceKim JW, Han GS, Lee SH, Lee DY, Kim YM. Sialoendoscopic treatment for radioiodine induced sialadenitis. Laryngoscope. 2007; 117: 133 ‐ 136.
dc.identifier.citedreferenceBhayani MK, Acharya V, Kongkiatkamon S, et al. Sialendoscopy for patients with radioiodine‐induced sialadenitis and xerostomia. Thyroid. 2015; 25: 834 ‐ 838.
dc.identifier.citedreferenceWu CB, Xi H, Zhou Q, Zhang LM. Sialendoscopy‐assisted treatment for radioiodine‐induced sialadenitis. J Oral Maxillofac Surg. 2015; 73: 475 ‐ 481.
dc.identifier.citedreferencePrendes BL, Orloff LA, Eisele DW. Therapeutic sialendoscopy for the management of radioiodine sialadenitis. Arch Otolaryngol Head Neck Surg. 2012; 138: 15 ‐ 19.
dc.identifier.citedreferenceBomeli SR, Schaitkin B, Carrau RL, Walvekar RR. Interventional sialendoscopy for treatment of radioiodine‐induced sialadenitis. Laryngoscope. 2009; 119: 864 ‐ 867.
dc.identifier.citedreferenceSweeney AR, Davis GE, Chang SH, Amadi AJ. Outcomes of endoscopic dacryocystorhinostomy in secondary acquired nasolacrimal duct obstruction: a case‐control study. Ophthalmic Plast Reconstr Surg. 2018; 34: 20 ‐ 25.
dc.identifier.citedreferenceJung SK, Kim YC, Cho WK, Paik JS, Yang SW. Surgical outcomes of endoscopic dacryocystorhinostomy: analysis of 1083 consecutive cases. Can J Ophthalmol. 2015; 50: 466 ‐ 470.
dc.identifier.citedreferenceLim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974‐2013. JAMA. 2017; 317: 1338 ‐ 1348.
dc.identifier.citedreferenceHaymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306: 721 ‐ 728.
dc.identifier.citedreferencePark KW, Wu JX, Du L, Leung AM, Yeh MW, Livhits MJ. Decreasing use of radioactive iodine for low‐risk thyroid cancer in California, 1999 to 2015. J Clin Endocrinol Metab. 2018; 103: 1095 ‐ 1101.
dc.identifier.citedreferenceHaugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016; 26: 1 ‐ 133.
dc.identifier.citedreferenceQaseem A, Kansagara D, Lin JS, Mustafa RA, Wilt TJ, Clinical Guidelines Committee of the American College of P. The development of clinical guidelines and guidance statements by the clinical guidelines Committee of the American College of physicians: update of methods. Ann Intern Med. 2019; 170: 863 ‐ 870.
dc.identifier.citedreferenceGillespie MB, Walvekar RR, Schaitkin BM, Eisele DW, eds. Gland‐Preserving Salivary Surgery: A Problem‐Based Approach. Cham, Switzerland: Springer International Publishing; 2018.
dc.identifier.citedreferenceMandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003; 13: 265 ‐ 271.
dc.identifier.citedreferenceNewkirk KA, Ringel MD, Wartofsky L, Burman KD. The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J. 2000; 79: 460 ‐ 468.
dc.identifier.citedreferenceVenturi S, Venturi M. Iodine in evolution of salivary glands and in oral health. Nutr Health. 2009; 20: 119 ‐ 134.
dc.identifier.citedreferenceRigler RG, Scanlon PW. Radiation parotitis from radioactive iodine therapy. Proc Staff Meet Mayo Clin. 1955; 30: 149 ‐ 153.
dc.identifier.citedreferenceLa Perle KM, Kim DC, Hall NC, et al. Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid. 2013; 23: 1029 ‐ 1036.
dc.identifier.citedreferenceAlmeida JP, Sanabria AE, Lima EN, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011; 33: 686 ‐ 690.
dc.identifier.citedreferenceRaza H, Khan AU, Hameed A, Khan A. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun. 2006; 27: 495 ‐ 499.
dc.identifier.citedreferenceChoi JS, Park IS, Kim SK, Lim JY, Kim YM. Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model. Thyroid. 2013; 23: 1445 ‐ 1451.
dc.identifier.citedreferenceCaglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002; 27: 767 ‐ 771.
dc.identifier.citedreferenceKim DW. Ultrasonographic features of the major salivary glands after radioactive iodine ablation in patients with papillary thyroid carcinoma. Ultrasound Med Biol. 2015; 41: 2640 ‐ 2645.
dc.identifier.citedreferenceJeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre‐ and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid. 2013; 23: 609 ‐ 616.
dc.identifier.citedreferenceMandel L. Hyposalivation: the roles of radioactive iodine and stapes surgery. J Oral Maxillofac Surg. 2013; 71: e76 ‐ e80.
dc.identifier.citedreferenceChoi JS, Lim HG, Kim YM, Lim MK, Lee HY, Lim JY. Usefulness of magnetic resonance sialography for the evaluation of radioactive iodine‐induced sialadenitis. Ann Surg Oncol. 2015; 22 ( Suppl 3 ): S1007 ‐ S1013.
dc.identifier.citedreferenceMandel SJ, Mandel L. Persistent sialadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg. 1999; 57: 738 ‐ 741.
dc.identifier.citedreferenceMandel L, Liu F. Salivary gland injury resulting from exposure to radioactive iodine: case reports. J Am Dent Assoc. 2007; 138: 1582 ‐ 1587.
dc.identifier.citedreferenceFard‐Esfahani A, Mirshekarpour H, Fallahi B, et al. The effect of high‐dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med. 2007; 32: 696 ‐ 699.
dc.identifier.citedreferenceZettinig G, Hanselmayer G, Fueger BJ, et al. Long‐term impairment of the lacrimal glands after radioiodine therapy: a cross‐sectional study. Eur J Nucl Med Mol Imaging. 2002; 29: 1428 ‐ 1432.
dc.identifier.citedreferenceda Fonseca FL, Yamanaka PK, Mazoti L, Arakawa‐Sugueno L, Kato JM, Matayoshi S. Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: a prospective comparative study. Head Neck. 2017; 39: 2381 ‐ 2396.
dc.identifier.citedreferenceSolans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001; 42: 738 ‐ 743.
dc.identifier.citedreferenceMorgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)‐treated patients. Ophthalmic Plast Reconstr Surg. 2005; 21: 337 ‐ 344.
dc.identifier.citedreferenceJonklaas J, Wang H, Esposito G. Salivary function after radioiodine therapy: poor correlation between symptoms and salivary scintigraphy. Front Endocrinol (Lausanne). 2015; 6: 100.
dc.identifier.citedreferenceJonklaas J. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction. Thyroid. 2014; 24: 1806 ‐ 1814.
dc.identifier.citedreferenceMcCready VR. An unusually high nasal uptake of radioactive iodine during treatment for carcinoma of the thyroid. Am J Roentgenol Radium Ther Nucl Med. 1966; 96: 593 ‐ 595.
dc.identifier.citedreferenceNorby EH, Neutze J, Van Nostrand D, Burman KD, Warren RW. Nasal radioiodine activity: a prospective study of frequency, intensity, and pattern. J Nucl Med. 1990; 31: 52 ‐ 54.
dc.identifier.citedreferenceLang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012; 151: 844 ‐ 850.
dc.identifier.citedreferenceHirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of nonthyroidal primary malignancy and the association with (131)I treatment in patients with differentiated thyroid cancer. Thyroid. 2016; 26: 1110 ‐ 1116.
dc.identifier.citedreferenceSawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta‐analysis. Thyroid. 2009; 19: 451 ‐ 457.
dc.identifier.citedreferenceBrown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008; 93: 504 ‐ 515.
dc.identifier.citedreferenceTeng CJ, Hu YW, Chen SC, et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population‐based study. J Natl Cancer Inst. 2015; 108: djv314.
dc.identifier.citedreferenceSilva‐Vieira M, Carrilho Vaz S, Esteves S, et al. Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role? Thyroid. 2017; 27: 1068 ‐ 1076.
dc.identifier.citedreferenceFallahi B, Adabi K, Majidi M, et al. Incidence of second primary malignancies during a long‐term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med. 2011; 36: 277 ‐ 282.
dc.identifier.citedreferenceKo KY, Kao CH, Lin CL, Huang WS, Yen RF. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population‐based cohort study. Eur J Nucl Med Mol Imaging. 2015; 42: 1172 ‐ 1178.
dc.identifier.citedreferenceCorrea NL, de Sa LV, de Mello RC. Estimation of second primary cancer risk after treatment with radioactive iodine for differentiated thyroid carcinoma. Thyroid. 2017; 27: 261 ‐ 270.
dc.identifier.citedreferenceMarti JL, Jain KS, Morris LG. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid. 2015; 25: 681 ‐ 687.
dc.identifier.citedreferenceIyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011; 117: 4439 ‐ 4446.
dc.identifier.citedreferenceClement SC, Peeters RP, Ronckers CM, et al. Intermediate and long‐term adverse effects of radioiodine therapy for differentiated thyroid carcinoma‐‐a systematic review. Cancer Treat Rev. 2015; 41: 925 ‐ 934.
dc.identifier.citedreferenceHenze M, Hittel JP. Mucoepidermoid carcinoma of the salivary glands after high dosage radiotherapy. Laryngorhinootologie. 2001; 80: 253 ‐ 256.
dc.identifier.citedreferenceRodriguez‐Cuevas S, Ocampo LB. A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Eur J Surg Oncol. 1995; 21: 692.
dc.identifier.citedreferenceKlubo‐Gwiezdzinska J, Van Nostrand D, Burman KD, et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid. 2010; 20: 647 ‐ 651.
dc.identifier.citedreferenceSaluja K, Butler RT, Pytynia KB, et al. Mucoepidermoid carcinoma post‐radioactive iodine treatment of papillary thyroid carcinoma: unique presentation and putative etiologic association. Hum Pathol. 2017; 68: 189 ‐ 192.
dc.identifier.citedreferenceKhang AR, Cho SW, Choi HS, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015; 83: 117 ‐ 123.
dc.identifier.citedreferenceRubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89: 1638 ‐ 1644.
dc.identifier.citedreferenceMolenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well‐differentiated thyroid cancer. J Clin Oncol. 2018; 36: 1831 ‐ 1839.
dc.identifier.citedreferenceBoucai L, Falcone J, Ukena J, et al. Radioactive iodine‐related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival. J Clin Endocrinol Metab. 2018; 103: 4216 ‐ 4223.
dc.identifier.citedreferenceCho YY, Lim J, Oh CM, et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population‐based study in Korea. Cancer. 2015; 121: 259 ‐ 268.
dc.identifier.citedreferenceVerkooijen RB, Smit JW, Romijn JA, Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol. 2006; 155: 801 ‐ 806.
dc.identifier.citedreferenceHyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007; 19: 83 ‐ 86.
dc.identifier.citedreferenceAn YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS. Symptomatic late‐onset sialadenitis after radioiodine therapy in thyroid cancer. Ann Nucl Med. 2013; 27: 386 ‐ 391.
dc.identifier.citedreferenceLee SM, Lee JW, Kim SY, Han SW, Bae WK. Prediction of risk for symptomatic sialadenitis by post‐therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer. Ann Nucl Med. 2013; 27: 700 ‐ 709.
dc.identifier.citedreferenceWu JQ, Feng HJ, Ouyang W, et al. Systematic evaluation of salivary gland damage following I‐131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow‐up. Nucl Med Commun. 2015; 36: 819 ‐ 826.
dc.identifier.citedreferenceDe Luca R, Vicidomini A, Trodella M, Tartaro G, Colella G. Sialoendoscopy: a viable treatment for I(131) induced sialoadenitis. Br J Oral Maxillofac Surg. 2014; 52: 641 ‐ 646.
dc.identifier.citedreferenceGrewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009; 50: 1605 ‐ 1610.
dc.identifier.citedreferenceVan Nostrand D. Sialoadenitis secondary to 131 I therapy for well‐differentiated thyroid cancer. Oral Dis. 2011; 17: 154 ‐ 161.
dc.identifier.citedreferenceMaruoka Y, Baba S, Isoda T, et al. A functional scoring system based on salivary gland scintigraphy for evaluating salivary gland dysfunction secondary to (131)I therapy in patients with differentiated thyroid carcinoma. J Clin Diagn Res. 2017; 11: TC23 ‐ TC28.
dc.identifier.citedreferenceBenn AM, Broadbent JM, Thomson WM. Occurrence and impact of xerostomia among dentate adult new Zealanders: findings from a national survey. Aust Dent J. 2015; 60: 362 ‐ 367.
dc.identifier.citedreferenceda Silva L, Kupek E, Peres KG. General health influences episodes of xerostomia: a prospective population‐based study. Community Dent Oral Epidemiol. 2017; 45: 153 ‐ 159.
dc.identifier.citedreferenceKloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002; 87: 5817 ‐ 5820.
dc.identifier.citedreferenceRosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013; 23: 617 ‐ 619.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed26417_am.pdf
Size:
949.4KB
Format:
PDF
View/Open
Name:
hed26417.pdf
Size:
1.011MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.